2024-01-01 2024-12-31 false Capium Accounts Production 1.1 13068362 2024-01-01 2024-12-31 13068362 bus:FullAccounts 2024-01-01 2024-12-31 13068362 bus:FRS102 2024-01-01 2024-12-31 13068362 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 13068362 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 13068362 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13068362 2024-01-01 2024-12-31 13068362 2024-12-31 13068362 bus:RegisteredOffice 2024-01-01 2024-12-31 13068362 core:WithinOneYear 2024-12-31 13068362 core:AfterOneYear 2024-12-31 13068362 1 2024-01-01 2024-12-31 13068362 bus:Director1 2024-01-01 2024-12-31 13068362 bus:Director1 2024-12-31 13068362 bus:Director1 2023-01-01 2023-12-31 13068362 2023-01-01 13068362 bus:LeadAgentIfApplicable 2024-01-01 2024-12-31 13068362 2023-01-01 2023-12-31 13068362 2023-12-31 13068362 core:WithinOneYear 2023-12-31 13068362 core:AfterOneYear 2023-12-31 13068362 bus:EntityAccountantsOrAuditors 2023-01-01 2023-12-31 13068362 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 13068362 bus:OrdinaryShareClass1 2024-12-31 13068362 bus:OrdinaryShareClass1 2023-01-01 2023-12-31 13068362 bus:OrdinaryShareClass1 2023-12-31 13068362 core:MotorCars 2024-01-01 2024-12-31 13068362 core:MotorCars 2024-12-31 13068362 core:MotorCars 2023-12-31 13068362 core:ComputerEquipment 2024-01-01 2024-12-31 13068362 core:ComputerEquipment 2024-12-31 13068362 core:ComputerEquipment 2023-12-31 13068362 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-12-31 13068362 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-12-31 13068362 core:CostValuation core:Non-currentFinancialInstruments 2024-12-31 13068362 core:CostValuation core:Non-currentFinancialInstruments 2023-12-31 13068362 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-12-31 13068362 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-12-31 13068362 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-12-31 13068362 core:Non-currentFinancialInstruments 2024-12-31 13068362 core:Non-currentFinancialInstruments 2023-12-31 13068362 core:ShareCapital 2024-12-31 13068362 core:ShareCapital 2023-12-31 13068362 core:RetainedEarningsAccumulatedLosses 2024-12-31 13068362 core:RetainedEarningsAccumulatedLosses 2023-12-31 13068362 dpl:Item1 2024-01-01 13068362 dpl:Item1 2024-12-31 13068362 dpl:Item1 2023-01-01 13068362 dpl:Item1 2023-12-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 13068362
England and Wales

 

 

 

GDT MEDICAL LTD



Unaudited Financial Statements
 


Period of accounts

Start date: 01 January 2024

End date: 31 December 2024

GDT MEDICAL LTD
Contents Page
For the year ended 31 December 2024
Director Giuseppe Di Taranto
Registered Number 13068362
Registered Office 58 Rosebank
Holyport Road
London
SW6 6LH
Accountants P and Co (Partners) LLP
18 Ensign Street
London
E1 8PA
1
Director's report and financial statements
The director presents his report and accounts for the year ended 31 December 2024.
Principal activities
Principal activity of the company during the financial year was of medical consultancy.
Director
The director who served the company throughout the year was as follows:
Giuseppe Di Taranto



On behalf of the board.


----------------------------------
Giuseppe Di Taranto
Director

Date approved: 29 September 2025
2
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of GDT MEDICAL LTD for the year ended 31 December 2024 which comprise of the Income Statement, the Statement of Financial Position and the related notes from the company's accounting records and from the information and explanations you have given us.


As a practising member firm of the Institute of Chartered Accountants in England and Wales, we are subject to its ethical and other professional requirements which are detailed at www.icaew.com/en/members/regulations-standards-and-guidance


This report is made solely to the Board of Directors of GDT MEDICAL LTD, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of GDT MEDICAL LTD and state those matters that we have agreed to state to the Board of Directors of GDT MEDICAL LTD, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than GDT MEDICAL LTD and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that GDT MEDICAL LTD has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of GDT MEDICAL LTD. You consider that GDT MEDICAL LTD is exempt from the statutory audit requirement for the year.


We have not been instructed to carry out an audit or a review of the accounts of GDT MEDICAL LTD . For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.









....................................................

P and Co (Partners) LLP
18 Ensign Street
London
E1 8PA
30 September 2025
3
 
 		 Notes
 		 2024
£		   2023
£
Turnover 654,429    480,807 
Cost of sales (10,349)   (2,784)
Gross profit 644,080    478,023 
Administrative expenses (140,582)   (158,832)
Operating profit 503,498    319,191 
Other interest receivable and similar income 12,011    2,344 
Profit/(Loss) on ordinary activities before taxation 515,509    321,535 
Tax on profit on ordinary activities (127,715)   (76,176)
Profit/(Loss) for the financial year 387,794    245,359 
 
4
 
 		 Notes
 		 2024
£		   2023
£
Fixed assets      
Tangible fixed assets 3 6,305    1,655 
6,305    1,655 
Current assets      
Debtors 4 19,683    14,469 
Cash at bank and in hand 758,849    603,687 
778,532    618,156 
Creditors: amount falling due within one year 5 (143,493)   (189,788)
Net current assets 635,039    428,368 
 
Total assets less current liabilities 641,344    430,023 
Net assets 641,344    430,023 
 

Capital and reserves 		     
Called up share capital 6 100    100 
Profit and loss account 641,244    429,923 
Shareholders' funds 641,344    430,023 
 


For the year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.
The financial statements were approved by the director on 29 September 2025 and were signed by:


-------------------------------
Giuseppe Di Taranto
Director
5
General Information
GDT MEDICAL LTD is a private company, limited by shares, registered in England and Wales, registration number 13068362, registration address 58 Rosebank, Holyport Road, London, SW6 6LH.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by Section 1A of the standard)
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Taxation
Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted
Tangible fixed assets

Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Motor Vehicles 25% Reducing Balance
Computer Equipment 25% Reducing Balance
Provisions
Provisions are recognised when the company has a present obligation as a result of a past event which it is more probable than not will result in an outflow of economic benefits that can be reasonably estimated.
2.

Average number of employees

Average number of employees during the year was 1 (2023 : 1).
3.

Tangible fixed assets

Cost or valuation Motor Vehicles   Computer Equipment   Total
  £   £   £
At 01 January 2024 475    2,794    3,269 
Additions -    6,104    6,104 
Disposals -    -    - 
At 31 December 2024 475    8,898    9,373 
Depreciation
At 01 January 2024 250    1,364    1,614 
Charge for year 56    1,398    1,454 
On disposals -    -    - 
At 31 December 2024 306    2,762    3,068 
Net book values
Closing balance as at 31 December 2024 169    6,136    6,305 
Opening balance as at 01 January 2024 225    1,430    1,655 


4.

Debtors: amounts falling due within one year

2024
£		   2023
£
Trade Debtors 19,683    8,909 
Director's Current Accounts -    5,560 
19,683    14,469 

5.

Creditors: amount falling due within one year

2024
£		   2023
£
Corporation Tax 127,715    76,176 
Accrued Expenses 15,778    109,397 
Deposits Held -    4,215 
143,493    189,788 

6.

Share Capital

Allotted, called up and fully paid
2024
£		   2023
£
100 Class A shares of £1.00 each 100    100 
100    100 

6